References

1. 1.
   KOUDSTAAL T，FUNKE-CHAMBOUR M，KREUTER M，et al.Pulmonary fibrosis：From pathogenesis to clinical decision-making［J］.Trends Mol Med，2023，29（12）：1076-1087.
2. 2.
   JIANG M，BU W，WANG X，et al.Pulmonary fibrosis：From mechanisms to therapies［J］.J Transl Med，2025，23（1）：515.
3. 3.
   ZHENG H，ZHANG L，WANG C，et al.Metabolic dysregulation in pulmonary fibrosis：Insights into amino acid contributions and therapeutic potential［J］.Cell Death Discov，2025，11（1）：411.
4. 4.
   WIJSENBEEK M，SUZUKI A，MAHER T M.Interstitial lung diseases［J］.Lancet，2022，400（10354）：769-786.
5. 5.
   CRUWYS S，HEIN P，HUMPHRIES B，et al.Drug discovery and development in idiopathic pulmonary fibrosis：The changing landscape［J］.Drug Discov Today，2024，29（11）：104207.
6. 6.
   SPAGNOLO P，KROPSKI J A，JONES M G，et al.Idiopathic pulmonary fibrosis：Disease mechanisms and drug development［J］.Pharmacol Ther，2021，222：107798.
7. 7.
   LUO L，ZHOU J，LIU X，et al.Development of modern Chinese medicine guided by molecular compatibility theory［J］.J Adv Res，2025，73：713-728.
8. 8.
   GE N，YAN G，SUN H，et al.Version updates of strategies for drug discovery based on effective constituents of traditional Chinese medicine［J］.Acupunct Herb Med，2023，3（3）：158-179.
9. 9.
   ZHANG S Y，ZHANG T，CHEN W，et al.A novel strategy for development and evaluation of traditional Chinese medicine based on genome-wide pan-receptor drug-target co-screening［J］.Acta Pharm Sin，2025，60（8）：2375-2388.
10. 10.
    WANG X，HUANG M，LU Y，et al.Integrated metabolomics and network pharmacology reveal the PI3K/Akt-mediated therapeutic mechanism of Abrus cantoniensis in lipid metabolism disorders［J］.Phytomedicine，2025，145：156953.
11. 11.
    WANG H，ZHANG L，LI X，et al.Machine learning prediction for constructing a universal multidimensional information library of Panax saponins （ginsenosides）［J］.Food Chem，2024，439：138106.
12. 12.
    YANG C，MAO X，WU J，et al.Amelioration of lung fibrosis by total flavonoids of Astragalus via inflammatory modulation and epithelium regeneration［J］.Am J Chinese Med，2023，51（2）：373-389.
13. 13.
    PENG J，LI X，FENG Q，et al.Anti-fibrotic effect of Cordyceps sinensis polysaccharide：Inhibiting HSC activation，TGF-beta1/Smad signalling，MMPs and TIMPs［J］.Exp Biol Med，2013，238（6）：668-677.
14. 14.
    KONG D，CHEN L，HUANG W，et al.Combined therapy with ligustrazine and paeonol mitigates hepatic fibrosis through destroying mitochondrial integrity of stellate cell［J］.Am J Transl Res，2020，12（4）：1255-1266.
15. 15.
    FENG F，LI N，CHENG P，et al.Tanshinone Ⅱ_A attenuates silica-induced pulmonary fibrosis via inhibition of TGF-beta1-Smad signaling pathway［J］.Biomed Pharmacother，2020，121：109586.
16. 16.
    WANG J，FANG Y，ZHOU Y，et al.The main bioactive compound of Panax notoginseng，notoginsenoside R₁，alleviates pulmonary fibrosis via MBD2/SHIP and STAT3 pathway［J］.J Funct Foods，2023，110：105881.
17. 17.
    ZHOU Q，JIANG L，SU T，et al.Overview of aristolochic acid nephropathy：An update［J］.Kidney Res Clin Pract，2023，42（5）：579-590.
18. 18.
    NEIDHART W，BREN V，BUR D，et al.The discovery of nonpeptide endothelin receptor antagonists.Progression towards bosentan［J］.Chimia，1996，50（11）：519-524.
19. 19.
    GORRIE D，BRAVO M，FAN L.The yin and yang of the natural product triptolide and its interactions with XPB，an essential protein for gene expression and DNA repair［J］.Genes-Basel，2024，15（10）：1287.
20. 20.
    LIU Y，SONG L，CHEN S，et al.Qingfeiyin decoction in idiopathic pulmonary fibrosis：Lung-targeted components and PI3K-Akt modulation［J］.J Ethnopharmacol，2025，351：120071.
21. 21.
    YANG M，ZHANG X，BAO S，et al.Maimendong decoction and its active ingredient，ophiopogonin D，alleviate bleomycin-induced pulmonary fibrosis by regulating the behavior of lung fibroblasts［J］.Chin Med，2025，20（1）：135.
22. 22.
    TIAN J，ZHOU N，WANG H，et al.Identification of anti-fibrotic compounds from Piper longum L via hollow fiber cell fishing and high-performance liquid chromatography with in vivo and in vitro validation［J］.Chin Med，2025，20（1）：127.
23. 23.
    LI Y，WAN C，LI F，et al.Indirubin attenuates sepsis by targeting the EGFR/SRC/PI3K and NF-κB/MAPK signaling pathways in macrophages［J］.Front Pharmacol，2025，16：1542061.
24. 24.
    WU S，YIN L，HAN K，et al.NAT10 accelerates pulmonary fibrosis through N4-acetylated TGFB1-initiated epithelial-to-mesenchymal transition upon ambient fine particulate matter exposure［J］.Environ Pollut，2023，322：121149.
25. 25.
    ZHOU J，CHEN Y，CHEN J，et al.NAT10 mediates cardiac fibrosis induced by myocardial infarction through ac4C modification of TGFBR1 mRNA［J］.Cell Biol Toxicol，2025，41（1）：125.
26. 26.
    ZHANG T，AN W，YOU S，et al.G protein-coupled receptors and traditional Chinese medicine：New thinks for the development of traditional Chinese medicine［J］.Chin Med，2024，19（1）：92.
27. 27.
    BI Z，LI H，LIANG Y，et al.Emerging paradigms for target discovery of traditional medicines：A genome-wide pan-GPCR perspective［J］.Innovation，2025，6（3）：100774.
28. 28.
    ZHANG P，ZHANG D，ZHOU W，et al.Network pharmacology：Towards the artificial intelligence-based precision traditional Chinese medicine［J］.Brief Bioinform，2023，25（1）：bbad518.
29. 29.
    ZHAO M，WANG Y，FANG C，et al.Investigating the mechanism of anti-hepatic fibrosis action of Chiyin Heji based on network pharmacology，molecular docking and experimental validation［J］.Nat Prod Res，2025，doi： .
30. 30.
    BRANCO I，CHOUPINA A.Bioinformatics：New tools and applications in life science and personalized medicine［J］.Appl Microbiol Biotechnol，2021，105（3）：937-951.
31. 31.
    ZHOU X，YU X，WAN C，et al.NINJ1 regulates platelet activation and PANoptosis in septic disseminated intravascular coagulation［J］.Int J Mol Sci，2023，24（4）：4168.
32. 32.
    LEE C，XIN G，LI F，et al.Calcium/p53/ninjurin 1 signaling mediates plasma membrane rupture of acinar cells in severe acute pancreatitis［J］.Int J Mol Sci，2023，24（14）：11554.
33. 33.
    BOUDREAU H E，CASTERLINE B W，RADA B，et al.Nox4 involvement in TGF-beta and Smad3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells［J］.Free Radic Biol Med，2012，53（7）：1489-1499.
34. 34.
    MILAM J E，KESHAMOUNI V G，PHAN S H，et al.PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis［J］.Am J Physiol Lung Cell Mol Physiol，2008，294（5）：L891-L901.
35. 35.
    REN Z，PAN X，LI J，et al.G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via Galpha（i/o） and downstream Smad2/3 and ERK1/2 phosphorylation［J］.Pharmacol Res，2023，191：106754.
36. 36.
    HUTTER S，VAN HAAFTEN W T，HUNERWADEL A，et al.Intestinal activation of pH-sensing receptor OGR1［GPR68］ contributes to fibrogenesis［J］.J Crohns Colitis，2018，12（11）：1348-1358.
37. 37.
    CUI X，SHI E，LI J，et al.GPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury［J］.Free Radic Biol Med，2022，189：58-70.
38. 38.
    CHEN Y，JIANG Q，XING X，et al.Macrophage derived galectin-3 promotes renal fibrosis and diabetic kidney disease by enhancing TGFbeta1 signaling［J］.Adv Sci，2025，12（35）：e04032.
39. 39.
    FENG H，ZHOU T T，LI Z W，et al.α-Hederin inhibits malignant transformation of intestinal epithelial cells by regulating SNX10-mediated glutamine metabolism［J］.Chin Tradit Herb Drugs，2023，54（7）：2135-2143.
40. 40.
    BAO S，CHEN T，CHEN J，et al.Multi-omics analysis reveals the mechanism of action of ophiopogonin D against pulmonary fibrosis［J］.Phytomedicine，2023，121：155078.
41. 41.
    YU Z Y ，CHEN W，LEN L，et al.Application of the gene-encoded natural diversity components repository（GNDC） in traditional Chinese medicine research［J］.Acta Pharm Sin，2025，60（11）：3408-3417.
42. 42.
    LI H，XIN G，ZHOU Q，et al.Qingkailing granule alleviates pulmonary fibrosis by inhibiting PI3K/Akt and SRC/STAT3 signaling pathways［J］.Bioorg Chem，2024，146：107286.
43. 43.
    YAO Q，LIN F，FAN X，et al.Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems［J］.Nat Commun，2018，9（1）：5032.
44. 44.
    MENG X，FU W，HUO M，et al.Insitu label-free visualization of tissue distributions of salidroside in multiple mouse organs by MALDI-MS imaging［J］.Int J Mass Spectrom，2020，453：116347.
45. 45.
    LIAO L，SONG X，WANG L，et al.Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy［J］.P Natl Acad Sci USA，2017，114（29）：E5986-E5994.
46. 46.
    FANG L，TAO W K，CHENG H Y，et al.Research progress on mechanism of uplink of traditional Chinese medicine and its brain targeting preparations［J］.Chin Tradit Herb Drugs，2023，54（10）：3312-3321.
47. 47.
    WANG Y L，WANG L Y，CHEN G G，et al.Tissue distribution of ferulie acid after oral administration of TangkueiBlood -supplementing decoction to rats［J］.Lishizhen Med Mater Med Res，2008，19（7）：1800-1802.
48. 48.
    ALVES L A，FERREIRA N，MARICATO V，et al.Graph neural networks as a potential tool in improving virtual screening programs［J］.Front Chem，2021，9：787194.
49. 49.
    ASMANI M，VELUMANI S，LI Y，et al.Fibrotic microtissue array to predict anti-fibrosis drug efficacy［J］.Nat Commun，2018，9（1）：2066.
50. 50.
    ZHU H，ZHOU R，CAO D，et al.A pharmacophore-guided deep learning approach for bioactive molecular generation［J］.Nat Commun，2023，14（1）：6234.
51. 51.
    YANG H，WANG Y，LIU W，et al.Genome-wide pan-GPCR cell libraries accelerate drug discovery［J］.Acta Pharm Sin B，2024，14（10）：4296-4311.
52. 52.
    CHEN W，SONG C，LENG L，et al.The application of artificial intelligence accelerates G protein-coupled receptor ligand discovery［J］.Engineering，2024，32：18-28.
53. 53.
    QIAO J，LI Y，ZENG R，et al.SARS-CoV-2 M（pro） inhibitors with antiviral activity in a transgenic mouse model［J］.Science，2021，371（6536）：1374-1378.
54. 54.
    YANG Z，WANG K，ZHANG G，et al.A deep learning model for structure-based bioactivity optimization and its application in the bioactivity optimization of a SARS-CoV-2 main protease inhibitor［J］.Eur J Med Chem，2025，291：117602.
55. 55.
    CHEN S，ZHANG O，JIANG C，et al.Deep lead optimization enveloped in protein pocket and its application in designing potent and selective ligands targeting LTK protein［J］.Nat Mach Intell，2025，7（3）：448-458.
56. 56.
    ZHOU Q，WU W，JIA K，et al.Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1［J］.Eur J Med Chem，2022，244：114830.
57. 57.
    SURA M B，CHENG Y X.Medicinal plant resin natural products：structural diversity and biological activities［J］.Nat Prod Rep，2024，41（10）：1471-1542.
58. 58.
    CHEN W，YU Z，LENG L，et al.Artificial intelligence-curated repository of gene-encoded natural diverse components from herbal medicines［J］.Innovation，2025，6（12）：101011.
59. 59.
    GHOSH S，CHISTI Y，BANERJEE U C.Production of shikimic acid［J］.Biotechnol Adv，2012，30（6）：1425-1431.
60. 60.
    YAN R，XIE B，XIE K，et al.Unravelling and reconstructing the biosynthetic pathway of bergenin［J］.Nat Commun，2024，15（1）：3539.
61. 61.
    WANG J，SONG J，ZHONG D，et al.Biomimetic synthesis of an antiviral cinnamoylphloroglucinol collection from Cleistocalyx operculatus：A synthetic strategy based on biogenetic building blocks［J］.Angew Chem Int Ed Engl，2023，62（50）：e202312568.
62. 62.
    DUAN F，XIN G，NIU H，et al.Chlorinated emodin as a natural antibacterial agent against drug-resistant bacteria through dual influence on bacterial cell membranes and DNA［J］.Sci Rep，2017，7（1）：12721.
63. 63.
    ZHANG K，YANG X，WANG Y，et al.Artificial intelligence in drug development［J］.Nat Med，2025，31（1）：45-59.
64. 64.
    ADAMS R，HENRY K E，SRIDHARAN A，et al.Prospective，multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis［J］.Nat Med，2022，28（7）：1455-1460.
65. 65.
    VERMA A A，STUKEL T A，COLACCI M，et al.Clinical evaluation of a machine learning-based early warning system for patient deterioration［J］.CMAJ，2024，196（30）：E1027-E1037.
66. 66.
    CUI H，HE Y，WANG Z，et al.Unveiling drug-induced osteotoxicity：A machine learning approach and webserver［J］.J Hazard Mater，2025，492：138044.
67. 67.
    DE SÁ A G C，LONG Y，PORTELLI S，et al.toxCSM：Comprehensive prediction of small molecule toxicity profiles［J］.Brief Bioinform，2022，23（5）：337.
68. 68.
    YAMAMOTO K，SATO T，HAO A，et al.Development of a natural product optimization strategy for inhibitors against MraY，a promising antibacterial target［J］.Nat Commun，2024，15（1）：5085.
69. 69.
    LEE C，WANG P H，TSENG Y J.Digital annealing optimization for natural product structure elucidation［J］.Brief Bioinform，2024，25（6）：bbae600.
70. 70.
    LIU C，WANG W，MIAO R，et al.Structure optimization of natural product piperine to obtain novel and potent analogs with anti-inflammation pain and urate-lowering effect［J］.Eur J Med Chem，2025，292：117649.
71. 71.
    XIN G，MING Y，JI C，et al.Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke［J］.Eur J Med Chem，2020，200：112462.
72. 72.
    LEE K，JANG J，SEO S，et al.Drug-likeness scoring based on unsupervised learning［J］.Chem Sci，2022，13（2）：554-565.
73. 73.
    RAVINDAR L，HASBULLAH S A，RAKESH K P，et al.Triazole hybrid compounds：A new frontier in malaria treatment［J］.Eur J Med Chem，2023，259：115694.
74. 74.
    WANG S，DONG G，SHENG C.Structural simplification of natural products［J］.Chem Rev，2019，119（6）：4180-4220.
75. 75.
    POON M，LORRAIN K，BROADHEAD A，et al.The LPAR1 antagonist，PIPE-791 produces antifibrotic effects in models of lung fibrosis［J］.Resp Res，2025，26（1）：265.
76. 76.
    ZHAN Z，WEI Z，YING B，et al.A near-infrared fluorescent probe for visualizing viscosity fluxes in live cells and idiopathic pulmonary fibrosis［J］.Sensor Actuat B-chem，2022，371：132575.
77. 77.
    LUAN C，SHEN Q，ROWELL N，et al.A real-time in situ demonstration of direct and indirect transformation pathways in CdTe magic-size clusters at room temperature［J］.Angew Chem Int Ed Engl，2022，61（35）：e202205784.
78. 78.
    BARTLETT D W，GILBERT A M.Translational PK-PD for targeted protein degradation［J］.Chem Soc Rev，2022，51（9）：3477-3486.
79. 79.
    LIANG J，WANG W F，ZHANG Y，et al.Fructooligosaccharides and fructans from Platycodon grandiflorum：Structural characterization，lung-oriented guidance and targetability［J］.Carbohydr Polym，2024，323：121457.
80. 80.
    LIANG J，LI Y，CHAI Y，et al.Revealing the Yin-Jing mystery veil of Platycodon grandiflorum by potentiating therapeutic effects and lung-oriented guidance property［J］.J Ethnopharmacol，2024，322：117587.
81. 81.
    ZHANG Y X.Preparation and cytotoxicity investigation of ligustrazine hydrochloride particles［D］.Chongqing：Chongqing Medical University，2014.
82. 82.
    JIANG H，ZHENG B，HU G，et al.Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connate extract［J］.J Pharm Anal，2024，14（9）：100971.
83. 83.
    CHEN G，WU J，HUANG H，et al.The dynamic distribution patterns and lung targeting efficiency in rats of 9 bioactive components in Siraitia grosvenorii［J］.J Ethnopharmacol，2025，340：119233.
84. 84.
    PRASAIN J K，PENG N，MOORE R，et al.Tissue distribution of puerarin and its conjugated metabolites in rats assessed by liquid chromatography-tandem mass spectrometry［J］.Phytomedicine，2009，16（1）：65-71.
85. 85.
    SHAN Y，LU J，QIAN H，et al.Immobilized protein strategies based on cell membrane chromatography and its application in discovering active and toxic substances in traditional Chinese medicine［J］.Pharmacol Res，2024，210：107492.
86. 86.
    SHAO S M，JI X，WANG X，et al.Two-dimensional cell membrane chromatography guided screening of myocardial protective compounds from Yindan Xinnaotong soft capsule［J］.Chin Med，2025，20（1）：5.
87. 87.
    SHEN Y，WEN L，ZHANG R，et al.Dihydrodiosgenin protects against experimental acute pancreatitis and associated lung injury through mitochondrial protection and PI3Kγ/Akt inhibition［J］.Br J Pharmacol，2018，175（10）：1621-1636.
88. 88.
    ZHAI X，WANG X，WANG L，et al.Treating different diseases with the same method-a traditional Chinese medicine concept analyzed for its biological basis［J］.Front Pharmacol，2020，11：946.
89. 89.
    GAO N，SUN Y J，PANG W T，et al.Analysis of collateral syndrome and organ fibrosis based on treating different diseases with the same method［J］.Tianjin J Tradit Chin Med，2024，41（11）：1394-1397.
90. 90.
    XUE X，LIU R，CAI Y，et al.Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m⁶A-regulated expression of a novel anti-fibrotic target ETV4［J］.J Hepatol，2025，83（1）：52-69.
91. 91.
    ZHAO X，KWAN J Y Y，YIP K，et al.Targeting metabolic dysregulation for fibrosis therapy［J］.Nat Rev Drug Discov，2020，19（1）：57-75.
92. 92.
    DU J，SUN J，LI N，et al.beta-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4［J］.Acta Pharmacol Sin，2021，42（7）：1090-1100.
93. 93.
    MIR S，ORMSBEE GOLDEN B D，GRIESS B J，et al.Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis，in part via Birc5 induction［J］.Breast Cancer Res，2022，24（1）：48.
94. 94.
    XU C G，YAN J，CHEN L Y，et al.Research progress in anti-hepatic fibrosis mechanism of Salvia miltiorrhiza［J］.Global Tradit Chin Med，2013，6（4）：305-308.
95. 95.
    DU X，SHI L，CHEN Z，et al.Astragaloside Ⅳ ameliorates isoprenaline-induced cardiac fibrosis in mice via modulating gut microbiota and fecal metabolites［J］.Front Cell Infect Microbiol，2022，12：836150.
96. 96.
    CHEN T，ZHOU L H，CUI W G.Progress in the application of betaine in cosmetics［J］.Detergent Cosmetics，2023，46（9）：55-61.
97. 97.
    CHEN J，ZHU G，XIAO W，et al.Ginsenoside Rg₁ ameliorates pancreatic injuries via the AMPK/mTOR pathway in vivo and in vitro［J］.Diabetes Metab Syndr Obes，2023，16：779-794.
98. 98.
    ZHANG L，LIU C，MENG X，et al.Smad2 protects against TGF-beta1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis［J］.Mol Cell Biochem，2015，400（1/2）：17-28.
99. 99.
    WAN L，PENG H，NI Y，et al.The miR-23b/27b/24-1 cluster inhibits hepatic fibrosis by inactivating hepatic stellate cells［J］.Cell Mol Gastroenterol Hepatol，2022，13（5）：1393-1412.
100. 100.
     ORUQAJ G，KARNATI S，KOTARKONDA L K，et al.Transforming growth factor-beta1 regulates peroxisomal genes/proteins via Smad signaling in idiopathic pulmonary fibrosis fibroblasts and transgenic mouse models［J］.Am J Pathol，2023，193（3）：259-274.
101. 101.
     ZHAO H，ZHANG Z，CHAI X，et al.Oxymatrine attenuates CCl₄-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways［J］.Int Immunopharmacol，2016，36：249-255.
102. 102.
     LIU L，LU W，MA Z，et al.Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-beta/Smad signaling pathway［J］.Int J Mol Med，2012，29（5）：815-822.
103. 103.
     YOON Y S，KIM S Y，KIM M J，et al.PPARgamma activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines［J］.Mucosal Immunol，2015，8（5）：1031-1046.
104. 104.
     NEMETH A，MOZES M M，CALVIER L，et al.The PPARgamma agonist pioglitazone prevents TGF-beta induced renal fibrosis by repressing EGR-1 and STAT3［J］.BMC Nephrol，2019，20（1）：245.
105. 105.
     GUO C，LAI L，MA B，et al.Notoginsenoside R₁ targets PPAR-gamma to inhibit hepatic stellate cell activation and ameliorates liver fibrosis［J］.Exp Cell Res，2024，437（1）：113992.
106. 106.
     ZENG Q，ZHOU T，HUANG W，et al.Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARgamma［J］.Sci Rep，2023，13（1）：14706.
107. 107.
     ZHANG S Y.Study on the mechanism of Huidouba inhibits hyperglycemia-induced HK-2 cell fibrosis by activating PPARγ mediated TGF-β/Smad signaling pathway［D］.Chengde：Chengde Medical University，2023.
108. 108.
     HUMPHRIES D C，MILLS R，DOBIE R，et al.Selective myeloid depletion of galectin-3 offers protection against acute and chronic lung injury［J］.Front Pharmacol，2021，12：715986.
109. 109.
     YUE S S，PENG A K，MA Z J，et al.The protective effects of naringenin on liver fibrosis by regulating TGF-β₁/Smad pathway［J］.Chin Pharmacol Bull，2022，38（2）：248-254.
110. 110.
     ZHANG X，LI B，ZHANG X，et al.18beta-Glycyrrhetinic acid monoglucuronide（GAMG）alleviates single-walled carbon nanotubes （SWCNT）-induced lung inflammation and fibrosis in mice through PI3K/Akt/NF-kappaB signaling pathway［J］.Ecotoxicol Environ Saf，2022，242：113858.
111. 111.
     REN J，LI J，LIU X，et al.Quercetin inhibits fibroblast activation and kidney fibrosis involving the suppression of mammalian target of rapamycin and beta-catenin signaling［J］.Sci Rep，2016，6：23968.
112. 112.
     LIU H，LI C Y，WANG X H，et al.Research progress of chlorogenic acid anti-fibrosis［J］.Guangdong Chem Ind，2025，52（8）：81-83.
113. 113.
     SHAFIEIAN M，CHEN S，WU S.Integrin-linked kinase mediates CTGF-induced epithelial to mesenchymal transition in alveolar type Ⅱ epithelial cells［J］.Pediatr Res，2015，77（4）：520-527.
114. 114.
     TAKAMURA N，RENAUD L，DA SILVEIRA W A ，et al.PDGF promotes dermal fibroblast activation via a novel mechanism mediated by signaling through MCHR1［J］.Front Immunol，2021，12：745308.
115. 115.
     KOK H M，FALKE L L，GOLDSCHMEDING R，et al.Targeting CTGF，EGF and PDGF pathways to prevent progression of kidney disease［J］.Nat Rev Nephrol，2014，10（12）：700-711.
116. 116.
     WANG D，HUANG R，CHENG X，et al.Tanshinone Ⅱ_A attenuates renal fibrosis and inflammation via altering expression of TGF-beta/Smad and NF-kappaB signaling pathway in 5/6 nephrectomized rats［J］.Int Immunopharmacol，2015，26（1）：4-12.
117. 117.
     ZHANG L，WEI W.Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony［J］.Pharmacol Ther，2020，207：107452.
118. 118.
     IMANISHI Y，MAEDA N，OTOGAWA K，et al.Herb medicine Inchin-ko-to （TJ-135） regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats［J］.J Hepatol，2004，41（2）：242-250.
119. 119.
     ALGANDABY M M，BREIKAA R M，EID B G，et al.Icariin protects against thioacetamide-induced liver fibrosis in rats：Implication of anti-angiogenic and anti-autophagic properties［J］.Pharmacol Rep，2017，69（4）：616-624.
120. 120.
     HARVEY A L，EDRADA-EBEL R，QUINN R J.The re-emergence of natural products for drug discovery in the genomics era［J］.Nat Rev Drug Discov，2015，14（2）：111-129.
121. 121.
     HONORIO K M，MODA T L，ANDRICOPULO A D.Pharmacokinetic properties and in silico ADME modeling in drug discovery［J］.Med Chem，2013，9（2）：163-176.
122. 122.
     CLARELLI F，LIANG J，MARTINECZ A，et al.Multi-scale modeling of drug binding kinetics to predict drug efficacy［J］.Cell Mol Life Sci，2020，77（3）：381-394.
123. 123.
     ABI HUSSEIN H ，GENEIX C，PETITJEAN M，et al.Global vision of druggability issues：Applications and perspectives［J］.Drug Discov Today，2017，22（2）：404-415.
124. 124.
     PALMER S M，SNYDER L，TODD J L，et al.Randomized，double-blind，placebo-controlled，phase 2 trial of BMS-986020，a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis［J］.Chest，2018，154（5）：1061-1069.
125. 125.
     CHENG P T W，KALTENBACH R F，ZHANG H，et al.Discovery of an oxycyclohexyl acid lysophosphatidic acid receptor 1 （LPA1） antagonist BMS-986278 for the treatment of pulmonary fibrotic diseases［J］.J Med Chem，2021，64（21）：15549-15581.
126. 126.
     MARTINEZ F J，CORTE T J，COTTIN V，et al.Design and rationale of a phase 3 trial for admilparant （BMS-986278），an oral lysophosphatidic acid receptor 1 antagonist，in patients with progressive pulmonary fibrosis：ALOFT-PPF［J］.Am J Respir Crit Care Med，2025，211（Abstracts）：A3543.
127. 127.
     GUO P，WANG Z，SUN L，et al.20 （S）-Protopanaxadiol alleviates DRP1-mediated mitochondrial dysfunction in a depressive model in vitro and in vivo via the SIRT1/PGC-1α signaling pathway［J］.Molecules，2024，29（21）：5085.
128. 128.
     KIM Y H，KIM Y C，JANG D，et al.Development of 20（S）-protopanaxadiol-loaded SNEDDS preconcentrate using comprehensive phase diagram for the enhanced dissolution and oral bioavailability［J］.Pharmaceutics，2020，12（4）：362.
129. 129.
     XIN G，ZHANG M，ZHONG Z，et al.Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration［J］.ACS Appl Mater Interfaces，2020，12（52）：57710-57720.